CONSTANT VOLUME DISCHARGE DEVICE
    23.
    发明公开
    CONSTANT VOLUME DISCHARGE DEVICE 有权
    ABGABEVORRICHTUNG MIT KONSTANTEM VOLUMEN

    公开(公告)号:EP2047877A1

    公开(公告)日:2009-04-15

    申请号:EP07791197.2

    申请日:2007-07-23

    IPC分类号: A61M5/315 A61M5/20

    摘要: There is provided a constant-volume dispenser which allows easy and reliable air removal from a syringe. A constant-volume dispensing syringe 10 includes a syringe 12 and a constant-volume dispenser 14. The constant-volume dispenser 14 includes an outer cylinder 26 which extends in the Arrow A direction; an inner cylinder 28 and a spring 30 which are housed in the outer cylinder 26; and a lid member 32 which is fitted to the outer cylinder 26; a pusher 34 which penetrates the outer cylinder 26, the inner cylinder 28 and the lid member 32; and an operation member 36 which is attached to the outer cylinder 26. In a preparation operation, the operation member 36 is moved from an initial position to a stopping position whereas in operations after the preparation operation, the operation member 36 is moved from a stand-by position to the stopping position. Due to this arrangement, the travel distance of the pusher 34 in the preparation operation is longer than the travel distance of the pusher 34 after the preparation operation.

    摘要翻译: 提供了恒定容量的分配器,其允许从注射器容易且可靠地排出空气。 定容量分配注射器10包括注射器12和恒定体积分配器14.恒定容量分配器14包括沿箭头A方向延伸的外筒26; 容纳在外筒26中的内筒28和弹簧30; 以及装配到外筒26的盖构件32; 穿过外筒26,内筒28和盖构件32的推动器34; 以及安装在外筒26上的操作构件36.在准备操作中,操作构件36从初始位置移动到停止位置,而在准备操作之后的操作中,操作构件36从支架 - 到位置到停止位置。 由于这种布置,推动器34在准备操作中的行进距离比准备操作之后的推动器34的行进距离长。

    CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    24.
    发明公开
    CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 有权
    CARBAZOLDERIVAT,SOLVAT DAVON UND PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON

    公开(公告)号:EP1852433A1

    公开(公告)日:2007-11-07

    申请号:EP05799893.2

    申请日:2005-10-28

    摘要: An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like.
    The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I):

    (In the formula (I), the ring A represents phenyl group or the like; X represents -O- or the like; Y represents =N- or the like; a and b represent methylene group or the like; both V and Z represent -O- or the like; W represents a C 1 -C 10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C 1 -C 6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R 1 represents methyl group or the like; R 2 represents methoxy group or the like; and R 3 represents carboxy group or the like.)

    摘要翻译: 本发明的目的是提供具有优异的脂肪组织减重效果,降血糖作用和降血脂作用的新颖的咔唑衍生物,溶剂化物或其药学上可接受的盐,其可用作脂肪的预防和/或治疗剂 肝脏,肥胖症,脂质代谢异常,内脏肥胖,糖尿病,高脂血症,葡萄糖耐量降低,高血压,非酒精性脂肪性肝病,非酒精性脂肪性肝炎等。 上述目的可以通过其咔唑衍生物,溶剂合物或其药学上可接受的盐来实现,其中咔唑衍生物由以下通式(I)表示:(式(I)中,环A表示苯基 X表示-O-等; Y表示= N-等; a和b表示亚甲基等; V和Z表示-O-等; W表示C 1〜 其中1或2个氢原子可以被苯基或C 1 -C 6烷基取代的C 10亚烷基; 1,2-亚苯基; 1,3-环己基等; R 1表示甲基 等等; R 2表示甲氧基等; R 3表示羧基等。)